iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Tables)

3 Months Ended

Sep. 30, 2022


	Three Months Ended
	September 30,
	2022		2021
Basic and diluted numerator:

Net loss attributable to iBio, Inc. from continuing operations	$	(7,537)	$	(5,188)
Preferred stock dividends – iBio CMO Preferred Tracking Stock		—		(66)
Net loss available to iBio, Inc. stockholders from continuing operations	$	(7,537)	$	(5,254)

Net loss available to iBio, Inc. stockholders from discontinued operations	$	(10,593)	$	(3,751)

Net loss available to iBio, Inc. stockholders - total	$	(18,130)	$	(9,005)

Basic and diluted denominator:

Weighted-average common shares outstanding		8,842		8,715

Per share amount - continuing operations	$	(0.85)	$	(0.60)
Per share amount - discontinued operations	$	(1.20)	$	(0.43)
Per share amount - total	$	(2.05)	$	(1.03)


	September 30,
	2022	2021

	(in thousands)
Stock options	923	576
Warrant issued under the Transaction	51	—
Restricted stock units	27	31
Shares excluded from the calculation of diluted loss per share	1,001	607